Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVULEN-28 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); Norethindrone: 5-14 hours (mean ~8 hours). Clinical context: Steady state reached within 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is primarily metabolized via CYP3A4; ethynodiol diacetate undergoes extensive first-pass metabolism, converted to norethindrone and other metabolites.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: ~50% as metabolites; Fecal/biliary: ~40% as conjugated metabolites; <1% unchanged in urine.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: 98-99% bound (albumin, SHBG); Norethindrone: 80-85% bound (albumin, SHBG).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: 2.3-3.2 L/kg (extensive tissue distribution); Norethindrone: 2.1-2.8 L/kg (distribution consistent with steroid hormones).
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Ethinyl estradiol: 38-48% (extensive first-pass metabolism); Norethindrone: 50-77% (oral bioavailability).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment; use with caution in severe renal impairment.
No data available for fictional drug ALYACEN 777.
Contraindicated in acute or chronic liver disease, including hepatic adenomas or carcinoma; discontinue if jaundice develops.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche; postmenarche: same as adult dosing after assessment of bone age and growth potential.
No data available for fictional drug ALYACEN 777.
Not indicated for use after menopause; no specific dose adjustment, but consider increased risk of thromboembolic events and estrogen-dependent neoplasms.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day), particularly in women over 35.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thrombotic disorders (e.g., venous thromboembolism, arterial thromboembolism), cardiovascular events, hepatic neoplasia, and gallbladder disease. Discontinue if jaundice or visual disturbances occur. Monitor for hypertension, depression, and fluid retention.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders; history of deep-vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hepatic adenoma or carcinoma; active liver disease; hypersensitivity to any component.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. May be taken with or without food. Grapefruit juice may increase estrogen levels; avoid excessive consumption.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester exposure is associated with increased risk of noncardiac birth defects (e.g., limb reduction defects) and cardiac anomalies (e.g., VSD, TGA). Postnatal studies show no increased risk with second or third trimester use. Avoid use in pregnancy due to known risks.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk in low amounts; M/P ratio ~0.3. No adverse effects reported in breastfed infants. Use with caution only if necessary.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No pharmacokinetic data inform dose adjustments; contraindicated in pregnancy.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Ovulen-28 (ethynodiol diacetate 1 mg/mestranol 0.1 mg) is a first-generation combined oral contraceptive. Counsel patients to take at the same time daily. If a dose is missed, follow standard missed pill protocol. Drug interactions with rifampin, anticonvulsants, and certain antibiotics may reduce efficacy. Monitor for hypertension, thromboembolism, and liver dysfunction. Not recommended for smokers over 35. Assess for contraindications including history of DVT, stroke, or migraine with aura.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time, even during your period.,If you miss a pill, take it as soon as you remember; if more than 12 hours late, use backup contraception.,Ovulen-28 does not protect against HIV or other STDs.,Common side effects include nausea, breast tenderness, and spotting; these usually improve.,Report symptoms of blood clots (leg pain, chest pain, sudden headache or vision changes) immediately.,Avoid smoking, especially if over 35, due to increased risk of serious side effects.,Tell your doctor about all other medications you take.,Store at room temperature away from moisture and heat.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVULEN-28 vs ALYACEN 777, answered by our medical review team.
OVULEN-28 is a Oral Contraceptive that works by Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVULEN-28 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVULEN-28 is: One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVULEN-28 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVULEN-28 is classified as Category C. First trimester exposure is associated with increased risk of noncardiac birth defects (e.g., limb reduction defects) and cardiac anomalies (e.g., VSD, TGA). Postnatal studies show. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.